Cutaneous T Cell Lymphomas: From Pathology to Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1946

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine, Divison of Hematology and Oncology, University of California, San Francisco, CA, USA
Interests: Hodgkin and non-Hodgkin lymphoma; cutaneous lymphoma; pre-clinical models and targeted therapy for mycosis fungoides and Sezary syndrome

E-Mail Website
Guest Editor
Division of Dermatology, City of Hope, Duarte, CA 91010, USA
Interests: tumor microenvironment in cutaneous lymphoma; advancing novel biologic therapies for cutaneous lymphoma; dermatopathology; mycosis fungoides; Sezary syndrome; lymphoma

Special Issue Information

Dear Colleagues,

Cutaneous T cell lymphomas (CTCL) are a rare subtype of non-Hodgkin lymphoma and a malignancy of skin-homing T cells. CTCL represents a heterogenous group of diseases that presents primarily in the skin at the time of diagnosis. Mycosis fungoides, the variants of mycosis fungoides, and Sezary syndrome (MF/SS) are the most common types, accounting for approximately 60% of all CTCLs. Early-stage mycosis fungoides may manifest as wide-spread, intensely pruritic skin lesions that significantly impact both quality of life and daily functioning. Advance-stage MF/SS can be life-threatening with a survival rate of 3.5 to 5.6 years. Due to its rarity, heterogeneous presentation, and clinical course, the clinical care of MF/SS presents unique challenges that are best addressed through a multidisciplinary approach.

In recent years, remarkable progress has been made in the field of CTCL. The revision of classification has contributed to a more precise diagnosis, prognosis, and treatment of CTCL. Employing state-of-the-art molecular and genetic techniques has provided insights into the potential genetic drivers and therapeutic targets. A deeper understanding of the functions of epigenetic modulation and tumor microenvironment has opened avenues for the discovery of novel therapies and the development of strategies to overcome drug resistance. Moreover, gaining insights into the mechanisms of action and treatment responses of novel agents, with the identification of prognostic biomarkers, is propelling us toward a more personalized therapeutic approach.

For this Special Issue of Cancers, we welcome original research and review articles that encompass the recent advances and address the future challenges in the diagnosis, biological insights, and treatment of CTCL.

Dr. Weiyun Z. Ai
Dr. Christiane Querfeld
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cutaneous T cell lymphoma
  • mycosis fungoides and Sezary syndrome
  • pathogenesis/biomarker discovery
  • tumor microenvironment
  • pre-clinical and clinical studies
  • biological insights

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1579 KiB  
Review
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma
by Louis Boafo Kwantwi, Steven T. Rosen and Christiane Querfeld
Cancers 2024, 16(19), 3368; https://doi.org/10.3390/cancers16193368 - 1 Oct 2024
Viewed by 1561
Abstract
Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the two common subtypes. Despite the substantial improvement in early-stage diagnosis and treatments, some patients still progress to the advanced stage with an elusive [...] Read more.
Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the two common subtypes. Despite the substantial improvement in early-stage diagnosis and treatments, some patients still progress to the advanced stage with an elusive underpinning mechanism. While this unsubstantiated disease mechanism coupled with diverse clinical outcomes poses challenges in disease management, emerging evidence has implicated the tumor microenvironment in the disease process, thus revealing a promising therapeutic potential of targeting the tumor microenvironment. Notably, malignant T cells can shape their microenvironment to dampen antitumor immunity, leading to Th2-dominated responses that promote tumor progression. This is largely orchestrated by alterations in cytokines expression patterns, genetic dysregulations, inhibitory effects of immune checkpoint molecules, and immunosuppressive cells. Herein, the recent insights into the determining factors in the CTCL tumor microenvironment that support their progression have been highlighted. Also, recent advances in strategies to target the CTCL tumor micromovement with the rationale of improving treatment efficacy have been discussed. Full article
(This article belongs to the Special Issue Cutaneous T Cell Lymphomas: From Pathology to Treatment)
Show Figures

Figure 1

Back to TopTop